Table 2 Univariate analyses of factors associated with BMD

Gender, N (%)

 Male

233 (18.6549%)

Reference

 Female

1016 (81.3451%)

-0.1082 (-0.1274, -0.0891) < 0.000001

Age, y

67.9416 ± 9.6115

-0.0027 (-0.0035, -0.0019) < 0.000001

BMI categorical, N (%)

  < 24 kg/m²

778 (62.2898%)

Reference

 24–28 kg/m²

358 (28.6629%)

0.0495 (0.0322, 0.0669) < 0.000001

  ≥ 28 kg/m²

113 (9.0472%)

0.0650 (0.0376, 0.0923) 0.000004

Platelet count, × 10⁹/L

185.1208 ± 61.0412

-0.0000 (-0.0002, 0.0001) 0.599814

Neutrophil count, × 10⁹/L

4.4744 ± 2.3500

0.0043 (0.0009, 0.0076) 0.012360

Lymphocyte count, × 10⁹/L

1.4060 ± 0.5580

0.0199 (0.0058, 0.0340) 0.005661

Monocyte count, × 10⁹/L

0.4122 ± 0.1880

0.0467 (0.0049, 0.0885) 0.028736

Albumin, g/L

40.2558 ± 4.7470

0.0022 (0.0005, 0.0038) 0.009684

Hemoglobin, g/L

124.2002 ± 16.7161

0.0010 (0.0005, 0.0014) 0.000059

Calcium, mmol/L

2.2704 ± 0.1783

-0.0074 (-0.0514, 0.0365) 0.739645

ALT, U/L

21.1433 ± 13.5909

0.0015 (0.0009, 0.0020) < 0.000001

AST, U/L

23.8199 ± 10.6814

0.0011 (0.0004, 0.0018) 0.003639

Cr, μmol/L

61.3947 ± 24.9772

0.0008 (0.0005, 0.0012) < 0.000001

CRP, mg/L

1.6649 ± 4.6003

0.0029 (-0.0002, 0.0061) 0.068442

BUN, mmol/L

6.2376 ± 1.8168

0.0032 (-0.0011, 0.0075) 0.145362

Glucose, mmol/L

6.0574 ± 1.9495

-0.0004 (-0.0044, 0.0036) 0.854772

Total cholesterol, mmol/L

4.5818 ± 1.0068

0.0020 (-0.0069, 0.0109) 0.660990

Triglyceride, mmol/L

1.3796 ± 0.9285

0.0099 (0.0002, 0.0196) 0.044713

High-density lipoprotein, mmol/L

1.4647 ± 0.3296

-0.0236 (-0.0508, 0.0037) 0.090335

Low-density lipoprotein, mmol/L

2.7438 ± 0.8069

0.0089 (-0.0023, 0.0200) 0.118669

Apolipoprotein A, g/L

1.3769 ± 0.2728

-0.0105 (-0.0435, 0.0224) 0.530965

Apolipoprotein B, g/L

0.8986 ± 0.2364

0.0122 (-0.0258, 0.0502) 0.529786

Homocysteine, μmol/L

13.1186 ± 6.8044

0.0010 (-0.0003, 0.0023) 0.126096

25(OH)D levels, ng/mL

20.8138 ± 8.1942

0.0026 (0.0017, 0.0036) < 0.000001

CCI score categorical, N (%)

 0

879 (70.3763%)

Reference

 1–2

194 (15.5324%)

-0.0172 (-0.0391, 0.0047) 0.124098

 3–4

107 (8.5669%)

-0.0048 (-0.0331, 0.0235) 0.740577

  ≥ 5

69 (5.5244%)

-0.0124 (-0.0469, 0.0221) 0.481759

Calcitonin usage, N (%)

 No

973 (77.9023%)

Reference

 Yes

276 (22.0977%)

-0.0259 (-0.0447, -0.0071) 0.007011

Surgery, N (%)

 No

636 (50.9207%)

Reference

 Yes

613 (49.0793%)

0.0008 (-0.0149, 0.0164) 0.921790

Primary diagnosis, N (%)

 OP without fractures

771 (61.7294%)

Reference

 OPF

478 (38.2706%)

-0.0334 (-0.0494, -0.0175) 0.000044

Serum uric acid, per 100 μmol/L increase

2.8861 ± 0.8379

0.0440 (0.0350, 0.0530) < 0.000001

Serum uric acid quartile, N (%)

 Q1(< 232 μmol/L)

311 (24.8999%)

Reference

 Q2(232–280 μmol/L)

311 (24.8999%)

0.0327 (0.0113, 0.0542) 0.002863

 Q3(280–336 μmol/L)

313 (25.0600%)

0.0677 (0.0462, 0.0891) < 0.000001

 Q4(> 336 μmol/L)

314 (25.1401%)

0.0924 (0.0710, 0.1139) < 0.000001